Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid.

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand Medicare coverage to include weight-loss drugs such as Novo Nordisks Wegovy and Eli

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden administration for Medicare coverage of weight-loss drugs such as Novo Nordisk's Wegovy.